﻿{"id":2602,"date":"2015-03-06T14:16:46","date_gmt":"2015-03-06T13:16:46","guid":{"rendered":"http:\/\/www.ematologialasapienza.it\/?p=2602"},"modified":"2023-11-14T15:27:02","modified_gmt":"2023-11-14T14:27:02","slug":"primi-risultati-del-protocollo-gimema-lal-1509","status":"publish","type":"post","link":"https:\/\/www.ematologialasapienza.it\/?p=2602","title":{"rendered":"Primi risultati del protocollo GIMEMA LAL 1509"},"content":{"rendered":"<p>Al 56mo congresso dell\u2019<em>American Society of Hematology <\/em>(<a href=\"http:\/\/www.hematology.org\/\" target=\"_blank\" rel=\"noopener\">ASH<\/a>) tenutosi a San Francisco dal <u>5 al 9 dicembre 2014<\/u>, la Dott.ssa<strong> Sabina Chiaretti<\/strong> dell\u2019Ematologia dell\u2019Universit\u00e0 \u2018<em>Sapienza<\/em>\u2019 di Roma ha presentato in sessione orale i primi risultati del <strong>protocollo GIMEMA LAL 1509<\/strong> \u2018<em>total therapy<\/em>\u2019 per pazienti adulti con leucemia acuta linfoblastica (LAL) Ph+*.<\/p>\n<p>Questo studio basato su una induzione con dasatinib pi\u00f9 steroidi e senza chemioterapia sistemica, seguito da un programma uniforme di terapia post-remissionale, rappresenta la naturale conseguenza dello studio GIMEMA LAL 1205 &#8211; \u2018<em>Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2019<\/em> &#8211; pubblicato su BLOOD nel 2011 (118: 6521-6528). Questa prima analisi dello studio, che ha confermato e ulteriormente migliorato i precedenti risultati riportati dal gruppo cooperatore italiano, ha destato molto interesse e discussione.<\/p>\n<p>Le principali conclusioni di questa prima analisi sono qui di seguito riassunte:<\/p>\n<ul>\n<li><em>A total therapy strategy is feasible for adult Ph+ ALL.<\/em><\/li>\n<li><em>All patients (100%) achieved a complete hematologic response within day +57 with dasatinib plus steroids.\u00a0<\/em><\/li>\n<li><em>Two patients lost the hematologic remision at day +85 (both p210+).<\/em><\/li>\n<li><em>No deaths in induction.<\/em><\/li>\n<li><em>18% of patients achieved a complete molecular response at the end of induction.<\/em><\/li>\n<li><em>A complete molecular response at day +85 was predictive of a better DFS.<\/em><\/li>\n<li><em>Patients with the p210 fusion protein responded less to TKI.<\/em><\/li>\n<li><em>At the first analysis, OS and DFS look promising.<\/em><\/li>\n<\/ul>\n<p>Oltre alla presentazione orale, lo studio \u00e8 stato altres\u00ec selezionato per la sessione speciale e conclusiva del congresso, \u2018<strong>Best of ASH<\/strong>\u2019, dove in 90 minuti sono state riassunte da <strong>Benjamin Ebert<\/strong> e <strong>Steven Lentz<\/strong>, 2014 <em>Annual Meeting Scientific Program Co-Chairs<\/em>, le pi\u00f9 importanti novit\u00e0 emerse a San Francisco e selezionate tra gli oltre 4000 abstracts. Una ulteriore soddisfazione a sottolineare la bont\u00e0 dal lavoro svolto dal gruppo cooperatore GIMEMA nell\u2019ambito delle LAL Ph+.<\/p>\n<p><em>Robin Fo\u00e0<\/em><\/p>\n<p>Ecco di seguito il testo completo dell&#8217;abstract<\/p>\n<p>&nbsp;<\/p>\n<p><strong>* First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients <\/strong><\/p>\n<p><strong>Sabina Chiaretti, MD, PhD<\/strong><sup>1*<\/sup>, Antonella Vitale, MD<sup>1*<\/sup>, Loredana Elia, PhD<sup>1*<\/sup>, Silvana Albino, Bsc<sup>1*<\/sup>, Alfonso Piciocchi, PhD<sup>2*<\/sup>, Paola Fazi, MD<sup>2*<\/sup>, Francesco Di Raimondo, MD<sup>3<\/sup>, Antonella Fornaro, MD<sup>4*<\/sup>, Francesco Fabbiano, MD<sup>5<\/sup>, Alfonso Maria D&#8217;Arco, MD<sup>6*<\/sup>, Giovanni Martinelli, MD<sup>7<\/sup>, Francesca Ronco, MD<sup>8*<\/sup>, Lidia Edwige Santoro, MD<sup>9*<\/sup>, Nicola Cascavilla, MD<sup>10*<\/sup>, Piero Galieni, MD<sup>11*<\/sup>, Alessandra Tedeschi, MD<sup>12*<\/sup>, Simona Sica, MD<sup>13*<\/sup>, Nicola Di Renzo, MD<sup>14<\/sup>, Angela Melpignano, MD<sup>15*<\/sup>, Angelo Michele Carella<sup>16<\/sup>, Felicetto Ferrara<sup>17<\/sup>, Marco Vignetti, MD<sup>2*<\/sup> and Robin Foa, MD<sup>1<\/sup><\/p>\n<p><sup>1<\/sup>Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Roma, Italy; <sup>2<\/sup>GIMEMA Data Center, GIMEMA Foundation, Roma, Italy; <sup>3<\/sup>Catania University, Hematology, &#8220;Ospedale Ferrarotto&#8221;, Catania, Italy; <sup>4<\/sup>Clinical Hematology &#8211; Azienda USL di Pescara, Pescara, Italy; <sup>5<\/sup>Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy; <sup>6<\/sup>Onco-hematology of Nocera Inferiore-plesso ospedaliero &#8211; Pagani (SA), Nocera Inferiore, Italy; <sup>7<\/sup>Institute of Hematology and Medical Oncology \u201cL. e A. Ser\u00e0gnoli\u201d, Bologna, Italy; <sup>8<\/sup>Hemato-oncology, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy; <sup>9<\/sup>Azienda Ospedaliera S.G.Moscati, Avellino, Italy; <sup>10<\/sup>Hematology &#8211; IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; <sup>11<\/sup>Hematology and Cellular Therapy, Ospedale&#8221;C. e G. Mazzoni&#8221;, Ascoli Piceno, Italy; <sup>12<\/sup>Niguarda Hospital, Division of Hematology, Milano, Italy; <sup>13<\/sup>Hematology, Universit\u00e0 Cattolica del Sacro Cuore &#8211; Policlinico A. Gemelli, Roma, Italy; <sup>14<\/sup>Hematology, ASL Le\/1 P.O. Vito Fazzi, Lecce, Italy;<br \/>\n<sup>15<\/sup>Ospedale &#8220;A. Perrino&#8221;, Brindisi, Italy; <sup>16<\/sup>Division of Hematology 1, IRCCS A.O.U. San Martino IST, Genova, Italy; <sup>17<\/sup>Azienda Ospedaliera di Rilievo Nazionale, Napoli, Italy.<\/p>\n<p><strong>Introduction:<\/strong> Ph+ ALL management has changed since the introduction of tyrosine kinase inhibitors (TKI). In the GIMEMA LAL 1509 protocol for adult Ph+ ALL, Dasatinib was administered in combination with steroids as induction treatment, and chemotherapy and\/or allogeneic transplantation (HSCT) was given if patients did not reach a sustained complete molecular response (CMR) after induction.<\/p>\n<p><strong>Methods:<\/strong> Steroids were administered from day -6 to day 31. Dasatinib (140 mg\/day) was given between days 1 and 84. Patients reaching a confirmed CMR (i.e. BCR\/ABL to ABL ratio=0) at the end of induction (day +85), continued Dasatinib for 6 additional months. Patients in complete hematologic remission (CHR), but not in CMR, were stratified according to HSCT eligibility: those with a promptly available donor underwent directly a HSCT; if the donor was not readily available, a consolidation cycle with clofarabine and cyclophosphamide was administered. HSCT non-eligible patients received two cycles of clofarabine and cyclophosphamide of 5 and 3 days, respectively. Dasatinib was administered until disease progression. Molecular testing was used to identify the presence of a BCR\/ABL transcript, define the fusion protein and quantify BCR\/ABL levels at baseline and at follow-up. Mutational screening was performed in relapsed cases.<\/p>\n<p><strong>Results:<\/strong> Sixty of the 64 enrolled patients were eligible. Median age was 41.9 years (range: 18.7-59.1), 34 were males and 26 females; the median WBC count was 12.5 x 10<sup>9<\/sup>\/l (range 1.4-178.0); the p190 fusion product was detected in 33 patients, p210 in 18 and p190\/p210 in 9. Median follow-up is 17.6 months (range 4.1-31.6). After the steroid pre-phase, 38 patients (63%) had a blast reduction \u226575%. At day 85, 58 patients achieved a CHR (97%) and 2 were non-responders (1 hematologic relapse and 1 disease progression): notably, both had a p210 fusion transcript. A CMR was obtained in 11 patients (18.6%): of these, 72% had a p190 fusion transcript. Overall, 24% of p190+ patients and 11% of p210+ or p190\/210+ cases obtained a CMR. As previously reported in other GIMEMA trials, no deaths in induction occurred. Among the CMR patients, only 1 experienced a hematologic relapse and harbored a T315I mutation. Among the 46 non-CMR cases, 17\/27 eligible patients underwent a HSCT, while 9 did not; 5 relapses occurred in the non-transplanted group, while 1 was observed in the HSCT group. Of the 19 HSCT non-eligible patients, 14 received the planned therapy: in this group, 2 relapses occurred. At 24 months, the overall survival (OS) is 69.1% (95%CI: 55.3-86.3), with a disease-free survival (DFS) at 18 months of 61.6% (95%CI: 47.6.0-79.8). A better DFS was observed in patients who obtained a CMR at day +85. Dasatinib exerted a rapid blast clearance, that was highly significant (p&lt;0.0001) between the onset and day +22, and between day +22 and +45; a significantly more rapid clearance (p=0.0005, p=0.0013 and p=0.001 at days +22, +45 and +57, respectively) was observed in patients who achieved a CMR at day +85, underlining the heterogeneous sensitivity of Ph+ ALL blasts to TKI. Importantly, a significantly greater clearance was observed in p190 (n=33) <em>vs<\/em> p190\/210 and p210 (n=27) cases (p=0.0008, p=0.0032, p=0.0031, p=0.0016, p=0.007 at diagnosis, days +22, +45, +57, and +85, respectively). Mutational screening was performed in 6\/12 patients who relapsed and mutations were detected in 5: 3 T315I and 2 V299L, of which 1 with a concomitant F317L. Overall, 12 relapses (5 in the p190 and 7 in the p210 subgroup) and 7 deaths in CR occurred, 5 of which in allografted patients. The median time to relapse was 6.7 months (range 0.3-22.5).<\/p>\n<p><strong>Conclusions<\/strong>: We confirm that a chemo-free induction approach for adult Ph+ ALL patients results in a very high CHR rate (97%), with no deaths in induction. In this Dasatinib-based protocol, a sustained CMR is achieved after induction in &gt;18% of cases, suggesting that a subset of patients may be spared further intensive treatment. We witnessed an increase in p190\/p210-p210+ cases compared to earlier studies; these patients showed a worse prognosis as underlined by a lower susceptibility to TKI, lower blast clearance and greater incidence of relapses (58%). At this first analysis, OS and DFS are at least comparable to those obtained in previous GIMEMA studies, despite the higher incidence of p210+ patients \u2013 which accounted for 45% of cases in this cohort \u2013 and which may require an intensified approach.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Al 56mo congresso dell\u2019American Society of Hematology (ASH) tenutosi a San Francisco dal 5 al 9 dicembre 2014, la Dott.ssa Sabina Chiaretti dell\u2019Ematologia dell\u2019Universit\u00e0 \u2018Sapienza\u2019 di Roma ha presentato in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[83,68],"_links":{"self":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/posts\/2602"}],"collection":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2602"}],"version-history":[{"count":2,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/posts\/2602\/revisions"}],"predecessor-version":[{"id":12095,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/posts\/2602\/revisions\/12095"}],"wp:attachment":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}